Basilea Pharmaceutica AG Allschwil (BSLN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH0011432447
Basilea Pharmaceutica AG Allschwil financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 208.00 m CHF | 232.00 m CHF |
| Gross profit | 169.00 m CHF | 193.00 m CHF |
| Operating income | 61.70 m CHF | 52.25 m CHF |
| EBIT | 61.00 m CHF | 51.00 m CHF |
| Net income | 77.00 m CHF | 40.00 m CHF |
| Diluted EPS – continuing operations | 5.59 CHF | 3.29 CHF |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Basilea Pharmaceutica AG Allschwil
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
More stocks
- Shenzhen Fine Made Electronics Group Co Ltd (300671.SZ)
- Syndax Pharmaceuticals Inc (SNDX)
- CHAPTERS Group (CHG.DE)
- SUBURBAN PROPANE PARTNERS LP (SPH)
- Keel Infrastructure Corp. (KEEL)
- Dalian Dalicap Technology Co Ltd (301566.SZ)
- Changzhou Aohong Electronics Co. Ltd. (605058.SS)
- Ategrity Specialty Insurance Co Holdings (ASIC)
- COMPASS Pathways plc (CMPS)
- Jefferson Capital, Inc. / DE (JCAP)
- Ladder Capital Corp (LADR)
- Xinjiang Lixin Energy Co. Ltd. A (001258.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.